Deals In Depth: October 2013
Eli Lilly agreed to co-promote Pfizer’s anti-NGF tanezumab for $200 million up front plus $350 million in regulatory milestones; private equity firms Avista and Nordic are taking Swiss pharmaco Acino private in a $439 million deal. Both biopharma and device financing increased in October vs. the previous month thanks to strong showings from IPOs and secondary offerings.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.